Launches of Zejula (niraparib) in its first European markets of Germany and the UK are expected in December, now that it has been granted approval by the EMA, as Tesaro Inc. mounts its challenge to AstraZeneca PLC 's Lynparza (olaparib) and seeks to establish its own position ahead of likely approval of another PARP inhibitor, Clovis Oncology Inc.'s Rubraca (rucaparib).
Tesaro Shakes Up EU PARP Market With Zejula Launches
EU approval signals the start of a marketing push against the combined might of AstraZeneca and Merck & Co – Tesaro believes it has the label to set it apart. For now, at least.
More from Anticancer
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.